IKZF1 and plasma cell myeloma: Interestingly, long-term bortezomib treatment blocked the lenalidomide-induced degradation of neo-substrate IKZF1/3 (61) and induced CRBN cleavage (6), which might attenuate the anti-myeloma effect of lenalidomide (Figure 2B).